Traxam 3.17% W/W Cutaneous Foam
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Traxam 3.17% w/w Cutaneous Foam Felbinac 3.17% w/w Cutaneous Foam
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Ingredient:
Felbinac (Biphenylacetic Acid) 3.17% w/w For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous foam (foam)
This medicine is ‘quick-break’ foam dispensed from cans which contain a concentrate of 3.17% felbinac in ethanol/aqueous vehicle with butane propellant.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
This medicine is a topical anti-inflammatory and analgesic. It is indicated for the relief of rheumatic pain, pain of non-serious arthritic conditions and soft tissue injury such as sprains, strains and contusions.
4.2 Posology and method of administration
Posology
Prescription Only Medicine Adult population
The foam should be dispensed onto the hand and rubbed lightly into the affected area(s). This medicine is formulated to break down into a clear liquid when warmed by contact with the skin.
Gently rub one golf-ball sized quantity of foam (one and a half inches (4cm) in diameter) into the affected area(s) 2 to 4 times a day.
The total daily dose should not exceed 25g of foam irrespective of the number of affected areas; a golf-ball size aliquot of foam weighs approximately 1 gram.
Hands should be washed following application of this medicine, unless they are the treatment site.
If symptoms do not resolve, it is advisable to review the patient to assess whether continued treatment is appropriate. Treatment should not extend beyond 6 weeks.
Elderly:
No special dosage recommendations are made for elderly patients.
Paediatric population
Safe use of felbinac in early childhood has not been established.
Pharmacy medicine Adult population
The foam should be dispensed onto the hand and rubbed lightly into the affected area(s).
This medicine is formulated to break down into a clear liquid when warmed by contact with the skin.
Gently rub one golf ball sized (one and a half inches (4cm) in diameter) quantity of foam into the affected area(s) 2 to 4 times a day.
The total daily dose should not exceed 25g of foam irrespective of the number of affected areas; a golf ball size aliquot of foam weighs approximately 1 gram.
Hands should be washed following application of this medicine, unless they are the treatment site.
Do not use for longer than 7 days.
Elderly:
No special dosage recommendations are made for elderly patients.
Paediatric population
Not recommended for use in children under 12 years of age.
4.3 Contraindications
Prescription Only Medicine
Hypersensitivity to the ingredients in this product. Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other nonsteroidal anti-inflammatory drugs.
Pharmacy Medicine
Hypersensitivity to the ingredients in this product. Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other nonsteroidal anti-inflammatory drugs.
Children under 12 years of age.
4.4 Special warnings and precautions for use
It should only be used on non-diseased skin. Use of this medicine should be limited to intact skin. Contact with mucous membranes and the eyes should be avoided. Patients should avoid actuation of the aerosol can near their face or eyes.
This medicine should not be applied with occlusive dressings or simultaneously to the same site as other topical preparations.
To avoid the possibility of photosensitivity, patients should be advised against excessive exposure to sunlight of treated areas.
Safe use of felbinac in early childhood has not been established.
4.5 Interaction with other medicinal products and other forms of interaction
Felbinac is highly protein bound. However, serum levels following topical application are extremely low and therefore clinical drug interactions are unlikely.
4.6 Fertility, pregnancy and lactation
Since the safety of felbinac in human pregnancy has not been established, it is not recommended for use in these circumstances. As with other non-steroidal anti-inflammatory agents which inhibit prostaglandin synthesis, dystocia and delayed parturition have been observed in animal studies when felbinac is administered late in pregnancy.
4.7 Effects on ability to drive and use machines
None
4.8 Undesirable effects
A low incidence of mild local irritation, erythema, dermatitis, pruritis and paraesthesia which recovers spontaneously upon cessation of treatment may be expected with this medicine.
Systemic side effects are rare; hypersensitivity reactions such as widespread rashes including urticaria and bronchospasm have been reported with felbinac. Gastrointestinal disturbances have been reported occasionally.
Skin photosensitivity has been reported.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
It is unlikely that this medicine could cause adverse systemic effects even if accidental ingestion should occur. Consult a doctor if ingestion is suspected.
5.1 Pharmacodynamic properties
Felbinac is an anti-inflammatory/analgesic agent which has been developed into a topical gel for local treatment of pain and inflammation associated with conditions of the musculo-skeletal system.
5.2 Pharmacokinetic properties
This medicine administered in a pharmacokinetic study achieves similar low circulating levels of felbinac to this medicine.
5.3 Preclinical safety data
Testing of biphenylacetic acid includes single and repeat dose studies, foetal toxicity and fertility studies, mutagenic and carcinogenic potential studies which show an acceptable toxicity profile for the active ingredient.
A primary dermal irritation study has shown this medicine to be non-irritant and that it can be safely applied to human skin.
This medicine is irritant to the eye but the irritation subsides within 7 days.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Ethanolamine USNF Ethanol 96% BP Purified Water BP Polawax A31 Softigen 767 Butane 40
6.2 Incompatibilities
None
6.3 Shelf life
12 Months
6.4 Special precautions for storage
This medicine is packed in a Pressurised container. Protect the canister from sunlight and do not expose to temperature above 50°C. Extremes of temperature can occur in motor cars. Do not pierce or burn canister even when empty. Do not refrigerate. Do not spray or use near any ignition source (e.g. naked flame, open fire) or while smoking.
This medicine should be stored below 25°C.
6.5 Nature and contents of container
Aluminium monobloc can with white enamel body, double grinded microflex internal lacquer and colourless overlacquer. Cans are fitted with a valve made of aluminium microflex and diptube and shave foam actuator.
Pack sizes: 25g, 30g, (Pharmacy)
Pack sizes: 50g, 100g, (Prescription Only)
6.6 Special precautions for disposal
Not applicable
7 MARKETING AUTHORISATION HOLDER
Mercury Pharmaceuticals Ltd
Capital House
85 King William Street
London
EC4N 7BL
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 12762/0086
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
09/04/1992 / 17/03/2003
10 DATE OF REVISION OF THE TEXT
09/05/2016